Simulations Plus, Inc.'s (SLP) CEO Shawn O'Connor on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/13/21
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical CompanyBusiness Wire • 04/07/21
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference CallBusiness Wire • 03/29/21
Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development SessionsBusiness Wire • 03/11/21
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety CollaborationBusiness Wire • 02/23/21
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools ConferenceBusiness Wire • 02/11/21
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical SciencesBusiness Wire • 01/26/21
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and TherapeuticsBusiness Wire • 01/14/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Simulations Plus, Inc. - SLPNewsfile Corp • 01/12/21
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection TreatmentsBusiness Wire • 01/12/21
Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 01/12/21